The antitumor immune response in HER-2 positive, metastatic breast cancer patients

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Juranic, Zorica D ^a   Neskovic Konstantinovic, Zora ^a   Stanojkovic, Tatjana P ^a   Zizak, Zeljko ^a   Srdic, Tatjana ^a   Stanojevic Bakic, Nevenka ^a   Milosevic, Dusanka ^a   Jovanovic, Danica ^a  

^a Inst for Serbia Oncology Radiology   (Yugoslavia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER PATIENT; CANCER RADIOTHERAPY; CELL SURVIVAL; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOTOXICITY; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MASTECTOMY; MEDICAL ASSESSMENT; METASTASIS POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; TUMOR IMMUNITY;

EID: 18144415120     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-3-13     Document Type: Article

References (19)

1. Thomas E, Berner G: Prognostic and predictive implications of HER2 status for breast cancer patients. Eur J Oncol Nurs 2000, 4:10-17.
2. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285-4289.
3. Baselga J, Albanell J, Molina MA, Arribas J: Mechanism of action of trastuzumab and scientific update. Semin Oncol 2001, 28:4-11.
4. Kumar R, Yarmand-Bagheri R: The role of HER2 in angiogenesis. Semin Oncol 2001, 28:27-32.
5. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM: Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993, 37:255-263.
6. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999, 26:60-70.
7. Devine DV: The regulation of complement on cell surfaces. Transfus Med Rev 1991, 5:123-131.
8. Juranic Z, Stanojevic-Bakic N, Neskovic-konstantinovic Z, Zizak Z, Stanojkovic T, Radulovic S, Milosevic D: The importance of antibody dependent cell-mediated cytotoxicity (ADCC) for breast cancer response to trastuzumab (Herceptin). Archive of Oncology (Conference paper - XXXIX Annual meeting of the oncologists of Serbia 14-15 November, 2002: Belgrade Yugoslavia) 2002:162-163.
9. Wang S, Saboorian MH, Frenkel E, Hynan L, Gokaslan ST, Ashfaq R: Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000, 53:374-381.
10. Ohno M, Abe T: Rapid colorimetric assay for the quantification of leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). J Immunol Methods 1991, 145:199-203.
11. Bell R, Verma S, Untch M, Cameron D, Smith I: Maximizing clinical benefit with trastuzumab. Semin Oncol 2004, 31: 35-44.
12. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
13. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG: Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000, 62:245-252.
14. Ferreira V, Molina MC, Valck C, Rojas A, Aguilar L, Ramirez G, Schwaeble W, Ferreira A: Role of calreticulin from parasites in its interaction with vertebrate hosts. Mol Immunol 2004, 40: 1279-1291.
15. Andrin C, Pinkoski MJ, Burns K, Atkinson EA, Krahenbuhl O, Hudig D, Fraser SA, Winkler U, Tschopp J, Opas M, Bleackley RC, Michalak M: Interaction between a Ca2+-binding protein calreticulin and perforin, a component of the cytotoxic T-cell granules. Biochemistry 1998, 37:10386-10394.
16. Fraser SA, Michalak M, Welch WH, Hudig D: Calreticulin, a component of the endoplasmic reticulum and of cytotoxic lymphocyte granules, regulates perforin-mediated lysis in the hemolytic model system. Biochem Cell Biol 1998, 76:881-887.
17. Fraser SA, Karimi R, Michalak M, Hudig D: Perforin lytic activity is controlled by calreticulin. J Immunol 2000, 164: 4150-4155.
18. Cooley J, Takayama TK, Shapiro SD, Schechter NM, Remold-O'Donnell E: The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites. Biochemistry 2001, 40:15762-15770.
19. Schimmer AD, Pedersen IM, Kitada S, Eksioglu-Demiralp E, Minden MD, Pinto R, Mah K, Andreeff M, Kim Y, Suh WS, Reed JC: Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res 2003, 63:1242-1248.